AC Immune Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from AC Immune SA
Access all reports
AC Immune SA is a clinical-stage biopharmaceutical company that specializes in precision medicine for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and NeuroOrphan diseases. These candidates target the misfolded proteins associated with these diseases, aiming to diagnose, treat, and prevent neurodegeneration. AC Immune SA is headquartered in Lausanne, Switzerland, and its shares are listed on the Nasdaq.
Key slides for AC Immune SA
AGM 2024 Presentation
AC Immune SA
AGM 2024 Presentation
AC Immune SA
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ACIU
Country
🇺🇸 United States